Otsuka details positive Phase 3 IgAN data as it awaits FDA decision
Otsuka Pharmaceuticals has shared the specifics of a late-stage win for a rare kidney disease treatment that’s on track to become its first wholly-owned product to be sold in the US. The biotech’s monoclonal antibody ...
Otsuka Pharmaceuticals has shared the specifics of a late-stage win for a rare kidney disease treatment that’s on track to become its first wholly-owned product to be sold in the US.
The biotech’s monoclonal antibody ...
